Loading...
NPI 1174009245 · Charleston, SC · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vikor Scientific, LLC is a clinical medical laboratory provider located in Charleston, South Carolina. This profile covers 10 Medicare and 70 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Vikor Scientific, LLC |
| Address | 22 Westedge St. |
| City | Charleston |
| State | SC |
| ZIP | 29403 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 12, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $27M |
| Medicare | $516.8K |
VIKOR SCIENTIFIC, LLC’s billing profile is concentrated in high-throughput molecular infectious disease testing: Medicare top codes include U0003 (4.5K claims) and U0005 (4.6K claims) and 87635 (805 claims), while Medicaid volume is dominated by 87798 (124.1K claims) and U0003 (153.5K claims). The mix of HCPCS/CPT codes points to a lab operation focused on nucleic-acid amplification and multiplex panels for respiratory pathogens, SARS‑CoV‑2, and a broad set of STI and bacterial targets rather than general clinical chemistry or anatomic pathology services.
Revenue concentration is high on both payers but differs by payer: the precomputed top-3 Medicare codes account for 94.2% of this provider’s Medicare revenue (U0003 at 65.2%, U0005 at 21.2%, 87635 at 7.8%), while the precomputed top-3 Medicaid codes account for 62.9% of Medicaid revenue (87798 at 34.3%, U0003 at 21.5%, 87481 at 7.0%). These shares indicate that a small set of molecular/infectious codes drive the vast majority of billed dollars to each payer.
The provider is overwhelmingly Medicaid-driven in scale: lifetime Medicare revenue is $516.8K versus lifetime Medicaid revenue of $27M, indicating that Medicaid comprises the dominant payer relationship on which the business is built. This profile should be treated as effectively single-payer dominant for revenue planning and network negotiations, with Medicare activity playing a much smaller role.
Competitive standing for Medicare-coded services is mixed: U0003 ranks #54 of 973 providers nationally (95th percentile) and U0005 ranks #72 of 1090 (93th percentile) while both are labeled in the file as having "typical, unremarkable volume"; 87635 is a clear national outlier at #133 of 9976 providers (99th percentile). In short, the provider shows notable national presence on a few Medicare molecular codes but otherwise is not a broad national laboratory competitor across many CPT/HCPCS codes.
In Medicaid, VIKOR SCIENTIFIC shows a dominant statewide presence across many molecular tests: numerous codes including 87798, U0003, 87481, 87633, 87653, 87641 and others rank #1 in-state and are described as "extreme outlier" or "notably above typical" volumes. Those state-level rankings and large claim counts (for example, 87798 at 124.1K claims and U0003 at 153.5K claims) indicate the provider captures a very large share of certain test volumes within South Carolina.
The code mix demonstrates operational breadth across respiratory multiplex panels, SARS‑CoV‑2 high-throughput testing, STI and vaginal microbiome assays, and bacterial resistance detection: Medicaid entries include large volumes for 87481 (61.6K claims), 87633 (12K claims), 87591 (42.5K claims) and 81514 (6.7K claims). This breadth suggests capability for both high-volume single-target runs (e.g., SARS‑CoV‑2) and multiplex diagnostic panels for public health and outpatient screening.
The dataset’s plain‑English outlier flags are important when evaluating network contracting and utilization management: multiple Medicaid codes are labeled "extreme outlier, far above typical state volume" and many additional codes are "notably above typical state volume," signaling that the provider’s Medicaid footprint is materially larger than most in-state peers for molecular infectious testing. These qualitative labels, combined with high claim counts and #1 in-state ranks, identify the provider as a major state-level supplier for these assays rather than a small regional lab.
VIKOR SCIENTIFIC’s NPI was enumerated on 2018-07-12 (~8 years ago), indicating several years of operational tenure; that period of activity alongside concentrated, high-volume Medicaid billing suggests the organization scaled molecular testing capacity after enumeration to serve broad state-level demand. Tenure plus the billing pattern supports classifying the entity as an established molecular diagnostics service provider in South Carolina rather than a recent or transient entrant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4,550 | $70 | $336.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 4,560 | $20 | $109.5K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 810 | $50 | $40.3K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 510 | $30 | $17.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 170 | $30 | $5.7K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 20 | $140 | $2.7K |
| 87505 | The lab analyst performs a test to detect three to five types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that cause gastrointestinal… | 20 | $130 | $2.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 40 | $30 | $1.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 10 | $30 | $440 |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 10 | $30 | $370 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
70 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 124,120 | $70 | $9.1M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 153,550 | $40 | $5.7M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 61,610 | $30 | $1.8M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 11,960 | $80 | $933K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 87,960 | $10 | $791.7K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 76,910 | $10 | $769K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 40,110 | $20 | $762K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 79,010 | $10 | $711.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 88,240 | $10 | $705.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 30,280 | $20 | $636K |
Showing 1–10 of 70
How this provider's Medicaid billing volume and revenue compare to other South Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. South Carolina median
70 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81201 | The lab analyst performs the technical lab test to analyze the entire gene sequence for adenomatous polyposis coli, also known as APC. | 2 | 10 | 690 | $510 | $348.5K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 2 | 10 | 530 | $640 | $341.1K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 2 | 10 | 690 | $460 | $318.6K |
| 81514 | The lab analyst performs the technical lab tests on a vaginal fluid specimen for quantitative real–time amplification of DNA markers for six bacterial species listed in the code descriptor, and… | 1 | 10 | 4,500 | $70 | $297.2K |
| 81404 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 5 molecular pathology code. | 2 | 10 | 750 | $380 | $288.8K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 2 | 10 | 530 | $520 | $277K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 90 | 730 | $60 | $275.7K |
| 81292 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2 gene. | 2 | 10 | 530 | $500 | $265.7K |
| 81405 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 6 molecular pathology code. | 2 | 10 | 740 | $340 | $252.3K |
| 81295 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 2, or MSH2 gene, also known as the colon cancer or nonpolyposis type 1 gene. | 2 | 10 | 530 | $410 | $217.7K |
Showing 1–10 of 70
Other providers in the same ZIP code as Vikor Scientific, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Disabilities Board Of Charleston County | SC | Developmentally Disabled Services Day Training Agency | $0 | $49.9M |
| Fetter Health Care Network, Inc. | SC | Federally Qualified Health Center (FQHC) | $0 | $5.8M |
| Nathan Seng | SC | Dentist | $0 | $1.6M |
| Charleston Pathology, P.A. | SC | Clinical Medical Laboratory | $248.5K | $385.5K |
| Phi Life Sciences LLC | SC | Clinical Medical Laboratory | $91.6K | $374.7K |
| Alexander Kent | SC | Ophthalmology Physician | $287.4K | $0 |
| Tracy Tipton | SC | Urology Physician | $249.8K | $0 |
| John Mitchell | SC | Critical Care Medicine (Internal Medicine) Physician | $216.5K | $0 |
| Joseph Lally | SC | Ophthalmology Physician | $202.5K | $0 |
| Todd Joye | SC | Interventional Pain Medicine Physician | $192.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.